IDO1 and cancer: Specifically, the treatment of the cancer cells with all three types of catalytic inhibitors increased the IDO1’s protein half-life with a t1/2 >44.367 ± 0.789 h, >100 h, and >36.400 ± 11.862 h, for EPA, LIN, and NAV, respectively, as compared to the physiologic turnover of IDO1 in FTC-133 cells (t1/2 > 15.140 ± 0.704 h) (Figure 2B, right lower panel).